A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
Study Details
Study Description
Brief Summary
This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Combination use of SRT with T-DXd Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced. Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg |
Drug: Combination use of SRT with T-DXd
Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.
Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg
|
Outcome Measures
Primary Outcome Measures
- Intracranial objective response rate(IC-ORR) [2 years]
Proportion of participants with a complete response (CR) or partial response (PR) for intracranial tumors as defined by response assessment in neuro-oncology brain metastases (RANO-BM) criteria.
Secondary Outcome Measures
- Intracranial CNS Progression Free Survival(IC-PFS) [2 years]
Time from treatment until the first date of intracranial disease progression or death due any cause. For participants whose disease has not progressed at the time of the analysis, censoring will be performed using the date of the last valid disease assessment.
- Progression Free Survival(PFS) [2 years]
Time from treatment until the first date of intracranial or extracranial disease progression or death due any cause. For participants whose disease has not progressed at the time of the analysis, censoring will be performed using the date of the last valid disease assessment.
- Overall survival(OS) [3 years]
Time from the treatment until to the date of death, regardless of the cause of death
- Percentage of Participants With Adverse Events Percentage of Participants With Adverse Events [2 years]
Treatment-related adverse events were assessed and graded according to CTCAE v. 5.0
- Health-related quality of life per FACT-BR [2 years]
Health-related quality of life was evaluated using the QLQ-C30 questionnaires to assess Health-related quality of life was evaluated using the FACT-BR questionnaires to assess the quality of life
- Local control rate [2 years]
The percentage of participants who have achieved complete response, partial response and stable disease according to RANO-BM criteria after treatment
- Neurocognitive function per HVLT-R [2 years]
Neurocognitive function was evaluated using HVLT-R test
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Pathologically confirmed HER2 positive advanced breast cancer
-
Age>18 years.
-
Brain metastases confirmed by enhanced brain MRI. Metastases number less than 15.
-
KPS≥70 or KPS ≥60 with neurologic symptoms caused by BM
-
Life expectancy of more than 6 months
-
Prior therapy of oral dexamethasone not exceeding 16mg/d
-
Time interval from prior therapy was more than 2 weeks, and evaluation of adverse events is no more than grade 1.
-
Screening laboratory values must meet the following criteria( and should be obtained within 28 days prior to registration):
-
Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L, Platelets≥ 90 x 109/L, Hemoglobin ≥ 90 g/L
-
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤2.5 x ULN without liver metastasis,≤ 5 x ULN with liver metastases
-
Serum BUN and creatinine ≤ 1.5 x Upper Limit of Normal (ULN)
-
LVEF ≥ 50%
-
QTcF < 480 ms
-
INR≤1.5×ULN，APTT≤1.5×ULN
- Signed the informed consent form prior to patient entry
Exclusion Criteria:
-
Leptomeningeal or hemorrhagic metastases
-
Uncontrolled epilepsy
-
Severe or uncontrolled disease: severe cardiovascular disease, end-stage renal disease, severe hepatic disease, history of immunodeficiency, including HIV positive, active HBV/HCV or other acquired congenital immunodeficiency disease, or organ transplantation history, active infection, etc.
-
History of allergy to treatment regimens
-
Pregnancy or lactation period， women of child-bearing age who are unwilling to accept contraceptive measures.
-
Inability to complete enhanced MRI
-
Not suitable for inclusion for specific reasons judged by sponsor
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fudan University Shanghai Cancer Center | Shanghai | China |
Sponsors and Collaborators
- Fudan University
Investigators
- Principal Investigator: Zhaozhi Yang, Fudan University
- Principal Investigator: Jiayi Chen, Ruijin Hospital affiliated to Shanghai Jiaotong University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FDRT-BC021